Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2016

View Archived Issues

Antimitotic compound leiodermatolide reduces pancreatic tumor weights in vivo

IdeS reduces HLA antibodies in kidney transplant candidates

Novel compound E-6887 shows promise for treating lupus

U.S. HHS awards contracts to support development of Zika virus diagnostic tests

Hemispherx Biopharma's NDA for rintatolimod receives approval in Argentina

Orally available peptides from Protagonist Therapeutics show promise for treating IBD

Biotron identifies new compounds in Zika program, signs agreement with NIAID

EMA validates Cempra's MAA for solithromycin

Oncology Venture updates progress of phase I trial of LiPlaCis

Innovative Targeting Solutions signs agreement with Janssen Biotech

FORMA Therapeutics describes HDAC inhibitors

Immune Therapeutics initiates Malawi study of LDN for prevention of cervical cancer

FDA grants breakthrough status to Stemline's SL-401

Cyon Therapeutics licenses Novartis' anti-PCSK9 antibody LGT-209

Temple University discovers novel 5-HT7 antagonists to treat inflammatory bowel disease

Pfizer to acquire AstraZeneca's small molecule anti-infectives business

FDA accepts Clovis' NDA for rucaparib

GlaxoSmithKline and Astex present a novel potent and reversible inhibitor of PAF acetylhydrolase

Biocardia merges with Tiger X Medical, forms new entity

AiCuris Anti-infective Cures' pritelivir achieves primary endpoint in phase I trial

Nanoantibiotics changes name to Biovie

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...